close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

23.49 +0.93 (+4.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ↗
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
News headline image
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered. 
Via Benzinga
News headline image
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst ↗
JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025. 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2025 ↗
 
Via Benzinga
News headline image
Analyst Expectations For Apellis Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings) ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts ↗
 
Via Benzinga
News headline image
A Glimpse of Apellis Pharmaceuticals's Earnings Potential ↗
 
Via Benzinga
News headline image
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday ↗
Sales of the company's top commercialized product didn't meet expectations. 
Via The Motley Fool
News headline image
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales ↗
The company is best known for its drug, Syfovre, a treatment for geographic atrophy. 
Via Investor's Business Daily
News headline image
The Latest Analyst Ratings For Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst ↗
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. 
Via The Motley Fool
News headline image
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga
News headline image
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
What's Going With Apellis Pharmaceuticals Stock Friday? ↗
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following... 
Via Benzinga
News headline image
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection ↗
The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today